

# ACTA MEDICINAE Speciál Kompletní literatura

## Kazuistiky 2013

- 2 **Zařazení enzalutamidu, nového antiandrogenu, do algoritmu léčby kastročně refrakterního karcinomu prostaty**  
MUDr. Michaela Matoušková Urocentrum Praha, s. r. o.
- 2 **Možnosti profylaxe recidivy ischemické cévní mozkové příhody**  
doc. MUDr. Martin Hutyra, Ph.D. I. interní kardiologická klinika FN a LF UP Olomouc  
doc. MUDr. Daniel Šaňák, Ph.D. Neurologická klinika FN a LF UP Olomouc
- 3 **Vildagliptin**  
MUDr. Kateřina Urbancová Diabetologická interní ambulance, s. r. o., Ostrava
- 3 **Management nežádoucích účinků při léčbě HCV infekce telaprevirem**  
MUDr. Soňa Fraňková Klinika hepatogastroenterologie, Transplantcentrum, Institut klinické a experimentální medicíny, Praha
- 3 **Fenotypy CHOPN s indikací inhalační kortikoidosteroidní léčby**  
MUDr. Radovan Kozel Městská nemocnice Ostrava
- 3 **Záchyt počínajícího rozvoje neuroleptického maligního syndromu po déletrvajícím kontinuálním podávání vysokodávkového tiapridu u pacienta s renální insuficiencí**  
PharmDr. Dalibor Černý, Ph.D. Oddělení klinické farmacie  
Nemocnice Na Homolce; Farmakologický ústav 1. LF UK a VFN v Praze  
PharmDr. Milada Halačová, Ph.D. Oddělení klinické farmacie  
Nemocnice Na Homolce; Ústav klinické biochemie 2. LF UK a FN Motol
- 4 **Inhibice PCSK9 a léčba hypercholesterolemie**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

# Zařazení enzalutamidu, nového antiandrogenu, do algoritmu léčby kastračně refrakterního karcinomu prostaty

MUDr. Michaela Matoušková Urocentrum Praha, s. r. o.

- 1 Tannock, I. F. – de Witt, R. – Berry, W. R., et al.: Docetaxel plus prednisone or Mitoxantrone plus prednisone for advanced prostate cancer. *New Engl J Med*, 2004, 351, s. 1502–1512.
- 2 Tran, C. – Ouk, S. – Clegg, N. J., et al.: Development of second-generation anti-androgen for treatment of advanced prostate cancer. *Science*, 2009, 324, s. 787–790.
- 3 Scher, H. I. – Fizazi, K. – Saad, F., et al.: Increased survival with enzalutamide in prostate cancer after chemotherapy. *NEJM*, 2012, 368, s. 38–48, doi: 10.1056/NEJMoa1209096.
- 4 Sternberg, C. N. – De Bono, J. S. – Chi, K. N. – Fizazi, K., et al.: Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. *J Clin Oncol*, 31, 2013, <http://meetinglibrary.asco.org/content/106560-134>.
- 5 Miller, K. – Scher, H. I. – Fizazi, K. – Basch, E. M., et al.: Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. *J Clin Oncol*, 31, 2013, <http://meetinglibrary.asco.org/content/106600-134>.
- 6 Llorca, Y. – Fizazi, K. – De Bono, J. S. – Forer, D., et al.: Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. *J Clin Oncol*, 31, 2013, <http://meetinglibrary.asco.org/content/113918-132>.
- 7 Scher, H. I. – Fizazi, K. – Saad, F., et al.: Impact of on-study corticosteroid use on efficacy and safety in the phase 3 AFFIRM study of enzalutamide, an androgen receptor inhibitor. *J Clin Oncol*, 31, 2013, <http://meetinglibrary.asco.org/content/107227-134>.
- 8 ClinicalTrials.gov: A safety and efficacy study of oral MDV3100 in chemotherapy-naïve patients with progressive metastatic prostate cancer (PREVAIL), dostupné z: <http://clinicaltrials.gov/show/NCT01212991>, vyhledáno 29. ledna 2013.

## Možnosti profylaxe recidivy ischemické cévní mozkové příhody

doc. MUDr. Martin Hutýra, Ph.D. I. interní kardiologická klinika FN a LF UP Olomouc

doc. MUDr. Daniel Šaňák, Ph.D. Neurologická klinika FN a LF UP Olomouc

- 1 Kral, M. – Herzig, R. – Sanak, D., et al.: Prevention of cardioembolic stroke in the Olomouc region of the Czech Republic. *Journal of the Neurological Sciences*, 2009, 285 (dopl. 1), S160.
- 2 Kimura, K. – Minematsu, K. – Yamaguchi, T.: Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. *J Neurol Neurosurg Psychiatry*, 2005, 76, s. 679–683.
- 3 Hylek, E. M. – Go, A. S. – Chang, Y. – Jensvold, N. G., et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med*, 2003, 349, s. 1019–1026.
- 4 O'Donnell, M. – Oczkowski, W. – Fang, J., et al.: Influence of pre-admission antithrombotic therapy on stroke severity in patients with atrial fibrillation: an observational study. *Lancet Neurol*, 2006, 5, s. 749–754.
- 5 Arsava, E. M. – Ballabio, E. – Benner, T., et al.: The causative classification of stroke system. *Neurology*, 2010, 75, s. 1277–1284.
- 6 Friberg, J. – Scharling, H. – Gadsboll, N. – Truelsen, T. – Jensen, et al.: Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). *Am J Cardiol*, 2004, 94, s. 889–894.
- 7 Miyasaka, Y. – Barnes, M. E. – Bailey, K. R., et al.: Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. *J Am Coll Cardiol*, 2007, 49, s. 986–992.
- 8 Conen, D. – Chae, C. U. – Glynn, R. J., et al.: Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. *JAMA*, 2011, 305, s. 2080–2087.
- 9 Gattellari, M. – Boumas, C. – Aitken, R.: Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (a Program of Research Informing Stroke Management). *Cerebrovasc Dis*, 2011, 32, s. 370–382.
- 10 Potpara, T. S. – Polovina, M. M. – Licina, M. M., et al.: Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "alone" atrial fibrillation: the Belgrade atrial fibrillation study. *Circ Arrhythm Electrophysiol*, 2012, 5, s. 319–326.
- 11 Potpara, T. S. – Stankovic, G. R. – Beleslin, B. D., et al.: A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation—implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. *Chest*, 2012, 141, s. 339–347.
- 12 The Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. *Neurology*, 2007, 69, s. 546–554.
- 13 Doufekias, E. – Segal, A. Z. – Kizer, J. R.: Cardiogenic and aortogenic brain embolism. *J Am Coll Cardiol*, 2008, 51, s. 1049–1059.
- 14 Camm, J. – Lip, G. Y. H. – Atar, D., et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. *European Heart Journal*, 2012, 33, s. 2719–2747, doi: 10.1093/eurheartj/ehs253.
- 15 Fuster, V. – Gersh, B. J. – Giuliani, E. R., et al.: The natural history of idiopathic dilated cardiomyopathy. *Am J Cardiol*, 1981, 47, s. 525–531.
- 16 Pepi, M. – Evangelista, A. – Nihoyannopoulos, P., et al.: Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism. *Eur J Echocardiogr*, 2010, 11, s. 461–464.
- 17 Meier, B. – Kalesan, B. – Mattle, H. P., et al.: Percutaneous closure of patent foramen ovale in cryptogenic embolism. *N Engl J Med*, 2013, 368, s. 1083–1091, doi: 10.1056/NEJMoa1211716.
- 18 Carroll, J. D. – Saver, J. L. – Thaler, D. E.: Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *N Engl J Med*, 2013, 368, s. 1092–1100, doi: 10.1056/NEJMoa1301440.
- 19 The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J*, 2012, 33, s. 2451–2496, doi: 10.1093/eurheartj/ehs109.
- 20 Hutýra, M. – Skála, T. – Šaňák, D., et al.: Persistent left superior vena cava connected through the left upper pulmonary vein to the left atrium: an unusual pathway for paradoxical embolization and a rare cause of recurrent transient ischaemic attack. *Eur J Echocardiogr*, 2010, doi: 10.1093/ejehocardi/jeq079.

## Vildagliptin

MUDr. Kateřina Urbancová Diabetologická interní ambulance, s. r. o., Ostrava

- 1 Pelikánová, T. – Bartoš, V., et al.: *Praktická diabetologie*. Praha, Maxdorf Jesenius, 2011.
- 2 Haluzík, M. – Svačina, Š.: *Inretinová léčba diabetu*. Praha, Mladá fronta,
- 3 Kvapil, M.: *Nová diabetologie*. Praha, Medical Tribune, 2012.
- 4 Kvapil, M. – Perušičová, J.: *Postprandiální glykemie*. Praha, Triton, 2006.

## Management nežádoucích účinků při léčbě HCV infekce telaprevirem

MUDr. Soňa Fraňková Klinika hepatogastroenterologie, Transplantcentrum, Institut klinické a experimentální medicíny, Praha

- 1 Manns, M. P., et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*, 2001, 358, s. 958–965.
- 2 Fried, M. W., et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*, 2002, 347, s. 975–982.
- 3 Ghany, M. G., et al.: Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology*, 2009, 49, s. 1335–1374.
- 4 EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol*, 2011, 55, s. 245–264.
- 5 Sherman, K. E., et al.: Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med*, 2011, 365, s. 1014–1024.
- 6 McHutchison, J. G., et al.: for PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med*, 2009, 360, s. 1827–1838.
- 7 Sulkowski, M. S., et al.: Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. *J Hepatol*, 2011, 54 (dopl. 1), s. 195.
- 8 Zeuzem, S., et al.: Telaprevir for retreatment of HCV infection. *N Engl J Med*, 2011, 364, s. 2417–2428.

## Fenotypy CHOPN s indikací inhalační kortikoidosteroidní léčby

MUDr. Radovan Kozel Městská nemocnice Ostrava

- 1 Musil, J. – Salajka, F. – Kos, S.: *Doporučený postup pro diagnostiku a léčbu CHOPN – stabilní fáze*. ČPFS ČLS JEP, 2000, abstrakt.
- 2 Koblížek, V., et al.: *CHOPN. Doporučený postup ČPFS pro diagnostiku a léčbu stabilní chronické obstrukční plicní nemoci*. Praha, Maxdorf, 2013.

## Záchyt počínajícího rozvoje neuroleptického maligního syndromu po déletrvajícím kontinuálním podávání vysokodávkového tiapridu u pacienta s renální insuficiencí

PharmDr. Dalibor Černý, Ph.D. Oddělení klinické farmacie

Nemocnice Na Homolce; Farmakologický ústav 1. LF UK a VFN v Praze

PharmDr. Milada Halačová, Ph.D. Oddělení klinické farmacie

Nemocnice Na Homolce; Ústav klinické biochemie 2. LF UK a FN Motol

- 1 Andreassen, M. D. – Pedersen, S.: Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS. *Ugeskr Laeger*, 2000, 162, s. 1366–1370.
- 2 Kasantikul, D. – Kanchananakhin, P.: Severe catatonia and neuroleptic malignant syndrome: report of 3 cases. *J Med Assoc Thai*, 1999, 82, s. 942–946.
- 3 Saunders, B. P. – Trewby, P. N.: The neuroleptic malignant syndrome: a missed diagnosis? *Br J Clin Pract*, 1993, 47, s. 170–171.
- 4 Gerbershagen, M. U., et al.: Malignant neuroleptic syndrome after haloperidol administration. *Anaesthetist*, 2001, 50, s. 329–332.
- 5 *Souhrn údajů o přípravku (SPC) Tiapridal*. Státní ústav pro kontrolu léčiv, www.sukl.cz, cit. 26. 8. 2013.
- 6 Seifertová, D.: Maligní neuroleptický syndrom. In: *Psychiatrie*, Praha, Tisig, 2002, s. 751–756.
- 7 Hýža, M. – Hanušková, V.: Atypický obraz neuroleptického maligního syndromu. *Psychiatrie pro praxi*, 2006, 6, s. 297–299.
- 8 Kopal, A., et al.: Maligní neuroleptický syndrom u pacientky s Parkinsonovou chorobou a akutní interkurentní infekcí. *Neurologie pro praxi*, 2006, 3, s. 158–159.
- 9 Roth, J., et al.: Postneuroleptické extrapyramidové syndromy. *Postgraduální medicína*, 2003, 4, <http://zdravi.e15.cz/clanek/postgraduální-medicína/postneuroleptické-extrapyramidové-syndromy-154100>.
- 10 Endow-Eyer, M. A.: Schizophrenia. In: *Applied therapeutics, The clinical use of drugs*, Philadelphia, Lippincot williams and wilkins, 2009, kapitola 78, s. 24.

# Inhibice PCSK9 a léčba hypercholesterolemie

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Lambert, G. – Charlton, F. – Rye, K.-A. – Piper, D. E.: Molecular basis of PCSK9 function. *Atherosclerosis*, 2009, 203, s. 1–7.
- 2 Abifadel, M. – Varret, M. – Rabés, J.-P. – Allard, D. – Ougeurram, K. – Devillers, M. – Cruaud, C. – Benjannet, S. – Wickham, L. – Erlich, D. – Derré, A. – Villéger, L. – Farnier, M. – Beucler, I. – Bruckert, E. – Chambaz, J. – Channu, B. – Lecerf, J.-M. – Luc, G. – Moulin, P. – Weissenbach, J. – Prat, A. – Krempf, M. – Junien, C. – Seidah, N. G. – Boilleau, C.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nature Genetics*, 2003, 34, s. 154–156.
- 3 Cohen, J. C. – Boerwinkle, E. – Mosley, T. H. – Hobbs, H. H.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *New England Journal of Medicine*, 2006, 354, s. 1264–1272.
- 4 Stein, E. A. – Gipe, D. – Bergeron, J. – Gaudet, D. – Weiss, R. – Dufour, R. – Wu, R. – Pordy, R.: REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. *Lancet*, 2012, 380, 7–13.
- 5 Sullivan, D. – Ollson, A. G. – Scott, R. – Kim, J. B. – Xue, A. – GebSKI, V. – Wasserman, S. M. – Stein, E. A.: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. *Journal of American Medical Association*, 2012, 308, s. 2497–2506.
- 6 Roth, E. M. – McKenney, J. M. – Hanotin, C. – Asset, G. – Stein, E. A.: Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. *New England Journal of Medicine*, 2012, 367, s. 1891–1900.
- 7 Raal, F. – Scott, R. – Somaratne, R. – Bridges, I. – Li, G. – Wasserman, S. M. – Stein, E. A.: Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation*, 2012, 126, s. 2408–2417.
- 8 Giugliano, R. P. – Desai, N. R. – Kohli, P. – Rogers, W. J. – Somaratne, R. – Huang, F. – Liu, T. – Mohanavelu, S. – Hoffman, E. B. – McDonald, S. T. – Sabatine, M. S.: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. *Lancet*, 2012, 380, s. 2007–2017.
- 9 Koren, M. J. – Scott, R. – Kim, J. B. – Knusel, B. – Liu, T. – Lei, L. – Bolognese, M. – Wasserman, S. M.: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. *Lancet*, 2012, 380, s. 1995–2006.
- 10 Frank-Kamenetsky, M. – Greffhorst, A. – Anderson, N. N. – Racie, T. S. – Bramlage, B. – Ankic, A. – Butler, D. – Charisse, K. – Dorkin, R. – Fan, Y. – Gamba-Vitalo, C. – Hadwiger, P. – Javaraman, M. – John, M. – Javaprakash, K. – Maier, M. – Nechev, L. – Rajeev, K. G. – Röhl, I. – Soutschek, J. – Tan, P. – Wong, J. – Wang, G. – Zimmermann, T. – de Fougerolles, A. – Vornlocher, H.-P. – Langer, R. – Anderson, D. G. – Manoharan, M. – Kotliansky, V. – Horton, J. D. – Fitzgerald, K.: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. *Proceedings of the National Academy of Sciences*, 2008, 105, s. 11915–11920.
- 11 Lindholm, M. W. – Elmén, J. – Fisker, N. – Hansen, H. F. – Persson, R. – Miller, M. R. – Rosenbohm, C. – Orum, H. – Straarup, E. M. – Koch, T.: Proprotein convertase subtilisin/kexin type 9 inhibition. *Molecular Therapy*, 2012, 20, s. 376–381.
- 12 Vogel, R. A.: PCSK9 inhibition. The next statin? *Journal of the American College of Cardiology*, 2012, 59, s. 2354–2355.
- 13 McKenney, J. M. – Koren, M. J. – Kereiakes, D. J. – Hanotin, C. – Ferrand, A. C. – Stein, E. A.: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. *Journal of the American College of Cardiology*, 2012, 59, s. 2344–2353.
- 14 Wivion, S. D. – Cannon, C. P.: The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. *Current Opinion in Lipidology*, 2006, 17, s. 628–630.
- 15 Cannon, C. P. – Shah, S. – Dansky, H. M. – Davidson, M. – Brinton, E. A. – Gotto, A. M. – Stepanavage, M. – Liu, S. X. – Gibbons, P. – Ashraf, T. B. – Zafarino, J. – Mitchel, Y. – Barter, P.: Safety of anacetrapib in patients with or at high risk for coronary heart disease. *New England Journal of Medicine*, 2010, 363, s. 2406–2415.
- 16 Chen, X.-W. – Wang, H. – Bajaj, K. – Zhang, P. – Meng, Z.-X. – Ma, D. – Bai, Y. – Liu, H.-H. – Adams, E. – Baines, A. – Yu, G. – Sartor, M. A. – Zhang, B. – Yi, Z. – Lin, J. – Young, S. G. – Schekman, R. – Ginsburg, D.: SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. *eLife*, 2013, 2, e00444.